Shots:

• The enrollment of the first P-III study is currently underway & has reached 85% of its enrollment goal. In a P-II study of 336 patients- NOV03 met its 1EP of efficacy i.e. improvement of total corneal fluorescein staining over control @8wks.
• Additionally- NOV03 showed improvement of certain symptoms- such as severity & frequency of dryness & burning/stinging of the eyes- over the entire duration of the P-II study with no notable safety events
• NOV03 is an investigational- water-free & preservative-free solution- based on patented EyeSol technology from Novaliq

­ Ref: PRNewswire | Image: SPJNews